A woman with advanced ovarian cancer has become the first person in the world to receive an experimental off-the-shelf cell therapy in a landmark clinical trial.
- A patient with advanced ovarian cancer became the first to receive the new cell therapy
- The treatment uses healthy donor immune cells engineered to attack cancer
- The Phase I trial will first evaluate safety before larger clinical studies
A woman with advanced ovarian cancer has become the first person in the world to receive an experimental off-the-shelf cell therapy, marking an important milestone in cancer immunotherapy.
The treatment, called ZI-MA4-1, is being tested in a first-in-human clinical trial to evaluate whether engineered immune cells from healthy donors can safely target hard-to-treat solid tumors.
The landmark study is currently enrolling patients with advanced ovarian, lung, head and neck, and certain sarcomas who have limited treatment options (1✔ ✔Trusted Source
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
According to researchers, the trial represents the first clinical evaluation of a new type of T-cell receptor-natural killer (TCR-NK) cell therapy, designed to combine the precision of targeted immunotherapy with the natural cancer-fighting ability of immune cells.
Advertisement
How Could This New Cell Therapy Change Ovarian Cancer Treatment?
The first patient has now received ZI-MA4-1, making this the world’s first clinical trial of an off-the-shelf cell therapy that combines engineered T-cell receptors with natural killer cells to treat advanced solid cancers.
Researchers say the Phase I study will mainly evaluate the treatment’s safety while exploring its potential to treat cancers that have stopped responding to standard therapies.
The trial represents an important step in testing a new type of cell therapy for ovarian cancer and other difficult-to-treat solid tumors, although much larger studies will be needed before the treatment can become widely available.
Advertisement
Key Details of the World’s First ZI-MA4-1 Cell Therapy Trial
|
Aspect |
Details |
|
Who received the treatment? |
Tracy Tomlinson, a 58-year-old woman from Greater Manchester with recurrent advanced ovarian cancer. She joined the study after surgery and multiple rounds of chemotherapy failed to stop the cancer from returning. |
|
What treatment did she receive? |
Three infusions of ZI-MA4-1, an experimental off-the-shelf TCR-NK cell therapy. A fourth infusion will depend on her scan results. |
|
Why is this trial historic? |
It is the first time anywhere in the world that ZI-MA4-1 has been given to a patient, making it the first clinical evaluation of Zelluna’s TCR-NK platform. |
|
Where is the trial being conducted? |
The Phase I ZIMA-101 study is led by The Christie NHS Foundation Trust in Manchester, with The Royal Marsden NHS Foundation Trust in London as the second study centre. |
|
What is the goal of the study? |
To evaluate the safety, tolerability, and preliminary anti-tumor activity of ZI-MA4-1 before larger clinical trials. |
|
Which cancers are included? |
Patients with advanced ovarian cancer, squamous non-small cell lung cancer, head and neck cancer, and synovial sarcoma whose disease has progressed despite standard treatment. |
|
Who developed the therapy? |
Norwegian biotechnology company Zelluna, which developed the therapy after receiving approval from the UK’s MHRA and Research Ethics Committee to begin the first-in-human trial. |
|
What do researchers hope to achieve? |
According to Chief Investigator Prof. Fiona Thistlethwaite, the study aims to establish the treatment’s safety and generate evidence that could support the development of future cell therapies for solid tumors. |
Advertisement
Which Patients Can Receive ZI-MA4-1 Cell Therapy?
The ZIMA-101 Phase I trial is testing ZI-MA4-1 in patients with advanced solid cancers who have few or no standard treatment options left.
The study aims to identify the safest dose while collecting early evidence on the treatment’s safety and anti-tumor activity.
To join the trial, participants must meet several eligibility criteria, including:
- Be between 18 and 75 years of age.
- Have advanced or metastatic ovarian cancer, squamous non-small cell lung cancer, head and neck cancer, or synovial sarcoma.
- Have tumors that express the MAGE-A4 protein.
- Be HLA-A*02:01 positive.
- Have cancer that has progressed despite standard treatment or have no approved treatment options available.
- Meet the study’s general health and fitness requirements before treatment.
Before receiving ZI-MA4-1, participants undergo lymphodepleting chemotherapy with cyclophosphamide and fludarabine to help the engineered immune cells work more effectively. Researchers will then monitor patients for side effects, determine the recommended dose, and assess early treatment responses.
Eligibility Criteria and Study Design of the ZIMA-101 Trial
|
Parameter |
Details |
|
Study phase |
Phase I, first-in-human |
|
Study design |
Dose-escalation followed by expansion cohort |
|
Age group |
18–75 years |
|
Eligible cancers |
Ovarian cancer, squamous NSCLC, head and neck cancer, synovial sarcoma |
|
Tumor requirement |
MAGE-A4-positive tumors |
|
Genetic requirement |
HLA-A*02:01 positive |
|
Previous treatment |
Disease progressed after standard therapy or no approved treatment available |
|
Treatment before infusion |
Lymphodepleting chemotherapy with cyclophosphamide and fludarabine |
|
Primary evaluation |
Safety, tolerability, dose selection, and preliminary anti-tumor activity |
What Makes ZI-MA4-1 Different from Existing Cell Therapies?
Unlike chemotherapy, which destroys both cancer cells and some healthy cells, cell therapy uses the body’s immune system to find and attack cancer more precisely. ZI-MA4-1 is different because it combines engineered immune cells with an “off-the-shelf” design, allowing treatment to be prepared in advance instead of being made separately for each patient.
According to researchers, this approach could make advanced cell therapy more accessible if future clinical trials prove it is safe and effective.
The table below explains how ZI-MA4-1 differs from conventional personalized cell therapies.
Comparison of Conventional Cell Therapy and ZI-MA4-1
|
Feature |
Conventional Personalized Cell Therapy |
ZI-MA4-1 Off-the-Shelf Cell Therapy |
|
Source of immune cells |
Uses the patient’s own immune cells |
Uses healthy donor-derived NK cells engineered with T-cell receptors |
|
Manufacturing |
Made individually for each patient |
Manufactured in advance and stored for use |
|
Treatment availability |
Patients wait while the therapy is produced |
Treatment can be available once a patient qualifies |
|
Cancer targeting |
Depends on the patient’s engineered immune cells |
Combines NK cells’ natural cancer-killing ability with TCRs that target the MAGE-A4 protein |
|
Suitable cancers |
Varies depending on the therapy |
Designed for MAGE-A4-positive solid tumors, including ovarian cancer, lung, head and neck cancers, and synovial sarcoma |
|
Potential advantage |
Personalized but time-consuming and difficult to scale |
Designed to improve access, simplify manufacturing, and support treatment for more patients |
Why Are Scientists Excited About Off-the-Shelf Cell Therapy?
Scientists have spent years trying to improve cell therapy for solid tumors, but many existing approaches have been difficult to manufacture, expensive, and less effective outside blood cancers.
According to the Immunotherapy Advances study, engineered TCR-NK cells may overcome several of these limitations because they combine the natural ability of NK cells to attack abnormal cells with the precision of T-cell receptors that recognize tumor-specific targets (2✔ ✔Trusted Source
Preclinical assessment of MAGE-A4-specific TCR-NK cells against solid tumors
The therapy is also designed to remain active even when some cancer cells reduce or lose the target protein, a common reason why tumors become resistant to treatment.
Researchers caution that ZI-MA4-1 is still an experimental treatment.
The current Phase I study is primarily assessing safety, determining the most appropriate dose, and collecting early evidence of anti-tumor activity before larger clinical trials can evaluate whether it improves long-term outcomes for patients with ovarian cancer and other advanced solid tumors.
Ovarian cancer remains one of the most difficult cancers to treat because it is often diagnosed after it has already spread beyond the ovaries.
According to a review published in the Journal of Ovarian Research, nearly 75% of patients are diagnosed at an advanced stage, when treatment becomes more challenging.
Although surgery and platinum-based chemotherapy remain the standard treatment, many patients eventually experience disease recurrence or develop resistance to treatment.(3✔ ✔Trusted Source
T-cell receptor therapy in ovarian cancer: concepts and challenges
Researchers say immunotherapy has improved outcomes in several cancers, but its success in ovarian cancer has been limited.
The disease creates an immune-suppressive environment that reduces the activity of cancer-fighting immune cells, making it harder for treatments such as immune checkpoint inhibitors to produce lasting responses.
This has encouraged scientists to develop more targeted cell therapy approaches, including engineered T-cell receptor therapies that recognize tumor-specific proteins such as MAGE-A4.
According to the same review, several early clinical studies targeting MAGE-A4 have shown encouraging signs in solid tumors, although most TCR-based therapies for ovarian cancer are still in Phase I or Phase I/II clinical trials. Researchers emphasize that further studies are needed before these treatments become part of routine cancer care.
What Could This Mean for India and the Future of Cancer Care?
Although the ZIMA-101 trial is currently being conducted in the United Kingdom, advances in cell therapy could eventually influence cancer treatment worldwide, including in India, where the burden of ovarian cancer continues to grow.
Ovarian cancer ranks among the top ten cancers in women across several Indian population-based cancer registries (4✔ ✔Trusted Source
Descriptive Epidemiology of Ovarian Cancers in India: A Report from National Cancer Registry Programme
The report also found that many women are diagnosed when the disease has already become locally advanced or spread to distant organs, making treatment more difficult. Surgery combined with chemotherapy remains the most common treatment approach.
Researchers also observed regional differences in ovarian cancer incidence across India, with some north-eastern states reporting higher occurrence at younger ages. The report highlights the need for improved awareness, earlier diagnosis, and continued research into newer treatment approaches that could improve patient outcomes.
Experts caution that ZI-MA4-1 is still an experimental therapy, and much more research is needed before it becomes widely available. Even so, the successful launch of the first-in-human trial represents an important step toward developing next-generation cell therapy for patients with advanced ovarian cancer and other difficult-to-treat solid tumors. If future clinical studies confirm its safety and effectiveness, off-the-shelf immune cell therapies could expand treatment options for patients who currently have few alternatives.
Frequently Asked Questions
Q: What is the new cell therapy being tested?
A: ZI-MA4-1 is an experimental off-the-shelf cell therapy that combines engineered T-cell receptors with natural killer (NK) cells to target cancer.
Q: Why is this trial considered a world first?
A: It is the first clinical trial to test this type of TCR-NK cell therapy in humans.
Q: Which cancers are included in the study?
A: The trial includes advanced ovarian cancer, squamous non-small cell lung cancer, head and neck cancer, and synovial sarcoma.
Q: What does ‘off-the-shelf’ cell therapy mean?
A: The therapy is made from healthy donor immune cells and prepared in advance, rather than being customized for each patient.
Q: Is this treatment available to everyone with ovarian cancer?
A: No. It is currently being tested in a Phase I clinical trial to evaluate safety and determine the appropriate dose.
Q: What could this mean for future cancer treatment?
A: If larger studies confirm its safety and effectiveness, off-the-shelf cell therapy could expand treatment options for patients with difficult-to-treat cancers.
References:
- A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies – (https://clinicaltrials.gov/study/NCT07613723?aggFilters=status:,phase)
- Preclinical assessment of MAGE-A4-specific TCR-NK cells against solid tumors – (https://academic.oup.com/immunotherapyadv/article/6/1/ltaf036/8380795)
- T-cell receptor therapy in ovarian cancer: concepts and challenges – (https://link.springer.com/article/10.1186/s13048-025-01831-y)
- Descriptive Epidemiology of Ovarian Cancers in India: A Report from National Cancer Registry Programme – (https://link.springer.com/article/10.1007/s40944-022-00694-1)
Source-Medindia